Article Details

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Retrieved on: 2022-10-17 11:35:11

Tags for this article:

Click the tags to see associated articles and topics

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat. View article details on HISWAI: https://seekingalpha.com/news/3891748-mereo-stock-rises-12-on-fda-fast-track-status-for-lung-disease-drug-alvelestat%3Fsource%3Dcontent_type%253Areact%257Cfirst_level_url%253Amarket-news%257Csection_asset%253Amain%257Csection%253Aon-the-move

Excerpt

The U.S. Food and Drug Administration (FDA) granted fast track designation to Mereo BioPharma alvelestat (MPH-966) to treat Alpha-1 Antitrypsin ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up